Zentiva, a leading European generics pharmaceutical company, Advent and GTCR – two leading global private equity investors – announce the sale of Zentiva by Advent to GTCR. Since acquiring Zentiva from Sanofi in 2018, Advent has worked closely with the management team to successfully transform the business, whilst investing to expand Zentiva’s portfolio of medicines and manufacturing footprint, both organically and through targeted M&A. This transformation programme has built Zentiva into a highly successful standalone business, with a strong focus on operational excellence and R&D capabilities, serving millions of patients across Europe.
Read the full article: Zentiva, a Leading European Generics Pharmaceutical Company, Announces Sale from Advent to GTCR //
Source: https://www.gtcr.com/zentiva-a-leading-european-generics-pharmaceutical-company-announces-sale-from-advent-to-gtcr/